Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Cinzia ScambiLisa Maria Bambara

Abstract

Recent studies have reported an imbalance between n6 and n3 fatty acids (AA and DHA) in subjects with CF. Alterations in fatty acid amounts are present in CFTR-expressing tissues, plasma and in circulating blood cells. It has been reported that the correction of polyunsaturated fatty acid deficiency reversed the organ pathologies observed in CF knockout mice. We describe a CF child with an unusual clinical course presenting high molar percentage of DHA in plasma and red cells membrane during supplementation with 5-methyltetrahydrofolate and vitamin B12.

References

Jan 1, 1988·Scandinavian Journal of Gastroenterology. Supplement·B BiggemannH J Bremer
Jul 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·M Tacconi, R J Wurtman
Feb 7, 1998·European Journal of Pediatrics·M RouletM Pilet
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·S D FreedmanJ G Alvarez
Sep 11, 2002·Biochemistry·Ofer EidelmanHarvey B Pollard
Feb 6, 2004·The New England Journal of Medicine·Steven D FreedmanBrian P O'Sullivan
Nov 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Liang N ZhangJohn F Engelhardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
M M UlaneV S Hubbard
American Journal of Physiology. Gastrointestinal and Liver Physiology
Satti BeharryPeter R Durie
Proceedings of the National Academy of Sciences of the United States of America
Steven D FreedmanJuan G Alvarez
© 2021 Meta ULC. All rights reserved